Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUDITH L WHITE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1316940018
CMS profile
14471
Location
KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$485.12

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $334.95 19
Food and Beverage $150.17 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $485.12 28

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUDITH L WHITE

NPI 1316940018 · CMS profile ID 14471

Allopathic & Osteopathic Physicians / Internal Medicine

KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $485.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925349 CMS
Eli Lilly and Company $2.0308/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925351 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925353 CMS
Eli Lilly and Company $10.2008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928825 CMS
Eli Lilly and Company $6.9508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928827 CMS
Eli Lilly and Company $3.0608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928829 CMS
Eli Lilly and Company $7.5108/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928831 CMS
Eli Lilly and Company $7.5208/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928833 CMS
Eli Lilly and Company $17.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932257 CMS
Eli Lilly and Company $21.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932259 CMS
Eli Lilly and Company $21.7608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932261 CMS
Eli Lilly and Company $3.0608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932263 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932265 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932267 CMS
Eli Lilly and Company $2.0308/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932269 CMS
Eli Lilly and Company $9.4508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657935631 CMS
Eli Lilly and Company $9.1808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942523 CMS
Eli Lilly and Company $10.2008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942525 CMS
Eli Lilly and Company $51.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945957 CMS
Eli Lilly and Company $15.3008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945959 CMS
Eli Lilly and Company $51.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945961 CMS
Eli Lilly and Company $84.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949343 CMS
Eli Lilly and Company $4.4608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949345 CMS
Eli Lilly and Company $128.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949347 CMS
Eli Lilly and Company $9.1808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949349 CMS
Eli Lilly and Company $4.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304149 CMS
Eli Lilly and Company $2.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304477 CMS
Eli Lilly and Company $1.2208/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.12 28
PY2021 $2,163.83 6
PY2022 $51.76 3
PY2024 $1,672.68 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $640,741.74 27
PY2024 Principal investigator $267,189.88 19
PY2023 Recipient $98.80 1
PY2023 Principal investigator $96,720.88 105
PY2022 Recipient $85.00 1
PY2022 Principal investigator $1,700,193.53 16,257
PY2021 Recipient $242.50 1
PY2021 Principal investigator $910,699.42 50
PY2020 Recipient $1,336.87 14
PY2020 Principal investigator $850,450.68 67
PY2019 Principal investigator $1,175,554.95 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $300.00 12/31/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314603
Principal investigator 1 Allergan, Inc. $72,887.36 12/31/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721314947
Principal investigator 1 AstraZeneca UK Limited $1,362.36 12/31/2020 Non-covered Recipient Entity
Compass Research
A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION No dispute reported 06/30/2026 736747105
Principal investigator 1 Allergan, Inc. $942.40 12/23/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721313873
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311811
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $51.00 12/10/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 713695623
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $364.00 12/10/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 713695649
Principal investigator 1 Eli Lilly and Company $1,910.33 11/19/2020 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728752565
Principal investigator 1 Eli Lilly and Company $2,650.00 11/17/2020 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728739737
Principal investigator 1 Nevro Corp. $2,048.00 11/04/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222665
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $760.36 10/27/2020 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 728751073
Principal investigator 1 Eli Lilly and Company $730.31 10/27/2020 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 728747651
Principal investigator 1 Eli Lilly and Company $262.75 10/27/2020 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728749915
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304717
Principal investigator 1 Allergan, Inc. $327.00 10/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721304049
Principal investigator 1 Allergan, Inc. $15,628.45 10/19/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303529
Principal investigator 1 Merck Sharp & Dohme Corporation $2,242.24 10/08/2020 Non-covered Recipient Entity
SYNEXUS RESEARCH
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 740786183
Principal investigator 1 Allergan, Inc. $115.00 09/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721300315
Principal investigator 1 Allergan, Inc. $12,217.00 09/18/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298537
Principal investigator 1 Nevro Corp. $200.00 09/16/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222661
Principal investigator 1 Nevro Corp. $200.00 09/16/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222707
Principal investigator 1 Allergan, Inc. $115.00 09/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721296787
Principal investigator 1 Allergan, Inc. $250.00 09/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721296791
Principal investigator 1 Eli Lilly and Company $310,760.00 09/15/2020 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728745751
Principal investigator 1 Allergan, Inc. $1,000.00 09/04/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721295569
Recipient Eli Lilly and Company $342.50 08/24/2020 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728721543
Principal investigator 1 Eli Lilly and Company $715.11 08/21/2020 Non-covered Recipient Entity
RADIANT RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728749259
Principal investigator 1 Eli Lilly and Company $1,084.98 08/20/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728735887
Principal investigator 1 Allergan, Inc. $9,702.30 08/19/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291155
Principal investigator 1 Allergan, Inc. $2,587.60 08/13/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721289845
Principal investigator 1 Allergan, Inc. $150.00 08/12/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289643
Principal investigator 1 Allergan, Inc. $230.00 08/12/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721289645
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $500.00 08/12/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 713688331
Principal investigator 1 Nevro Corp. $8,002.24 08/12/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial CA2016-5 US PDN1 No dispute reported 06/30/2026 717222673
Recipient Eli Lilly and Company $87.00 07/31/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728721299
Principal investigator 1 Eli Lilly and Company $2,557.72 07/28/2020 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 728751649
Principal investigator 1 Allergan, Inc. $18,304.60 07/20/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285275
Principal investigator 1 Allergan, Inc. $517.10 07/14/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721283653
Principal investigator 1 Nevro Corp. $75.00 07/14/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial - CA2016-5 US PDN1 No dispute reported 06/30/2026 717222671
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $2,073.32 06/25/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 728735891
Principal investigator 1 Eli Lilly and Company $2,881.80 06/25/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 728741895
Principal investigator 1 Allergan, Inc. $16,520.50 06/24/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721281505
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $423.00 06/09/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 713684589
Principal investigator 1 Nevro Corp. $23,150.40 06/02/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222653
Principal investigator 1 Allergan, Inc. $6,088.55 05/25/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721276795
Principal investigator 1 Allergan, Inc. $420.00 04/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721273213
Principal investigator 1 Allergan, Inc. $16,868.20 04/20/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271211
Principal investigator 1 Nevro Corp. $400.00 04/15/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222663
Principal investigator 1 Allergan, Inc. $16,019.85 03/18/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265425
Principal investigator 1 Eli Lilly and Company $7,056.55 03/18/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728741893
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262813
Principal investigator 1 Nevro Corp. $75.00 03/05/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222659
Principal investigator 1 AstraZeneca UK Limited $1,526.00 03/03/2020 Non-covered Recipient Entity
Compass Research
A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION No dispute reported 06/30/2026 736737143
Principal investigator 1 Allergan, Inc. $139,346.00 02/24/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721259141
Principal investigator 1 Mitsubishi Tanabe Pharma Development America, Inc. $20,066.80 02/24/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFECT OF MT-8554 ON THE FREQUENCY AND SEVERITY OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL WOMEN No dispute reported 06/30/2026 749850819
Recipient Ichnos Sciences Inc. $13.92 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483545
Recipient Ichnos Sciences Inc. $60.59 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483547
Recipient Ichnos Sciences Inc. $93.74 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483549
Recipient Ichnos Sciences Inc. $187.35 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483551
Recipient Ichnos Sciences Inc. $40.52 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483553
Recipient Ichnos Sciences Inc. $25.84 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483555
Recipient Ichnos Sciences Inc. $35.88 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483557
Recipient Ichnos Sciences Inc. $5.98 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483559
Recipient Ichnos Sciences Inc. $8.14 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483561
Recipient Ichnos Sciences Inc. $7.00 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483563
Recipient Ichnos Sciences Inc. $423.58 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483565
Recipient Ichnos Sciences Inc. $4.83 02/11/2020 Covered Recipient Physician GBR830-204 No dispute reported 06/30/2026 733483567
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,500.00 02/03/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Endometriosis Dose finding EU & US JP CN No dispute reported 06/30/2026 713676921
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $400.00 02/03/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Endometriosis Dose finding EU & US JP CN No dispute reported 06/30/2026 713676941
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $500.00 02/03/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Endometriosis Dose finding EU & US JP CN No dispute reported 06/30/2026 713676949
Principal investigator 1 Nevro Corp. $5,328.00 01/31/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222667
Principal investigator 1 Nevro Corp. $80,458.28 01/31/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222669
Principal investigator 1 Allergan, Inc. $115.00 01/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721254823
Principal investigator 1 Nevro Corp. $75.00 01/27/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222657
Principal investigator 1 Mitsubishi Tanabe Pharma Development America, Inc. $7,763.24 01/22/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AN OPEN-LABEL, LONG TERM EXTENSION STUDY OF MT-8554 IN POSTMENOPAUSAL WOMEN EXPERIENCING MODERATE TO SEVERE VASOMOTOR SYMPTOMS WHO COMPLETED STUDY MT-8554-A01 No dispute reported 06/30/2026 749850821
Principal investigator 1 Allergan, Inc. $6,562.60 01/20/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248623
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,000.00 01/16/2020 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 713675747
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721246565
Principal investigator 1 Eli Lilly and Company $5,615.30 01/14/2020 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728733935
Principal investigator 1 Nevro Corp. $75.00 01/07/2020 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 717222655
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,851.08 01/01/2020 Non-covered Recipient Entity
ACCELERATED ENROLLMENT SOLUTIONS
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH No dispute reported 06/30/2026 721489015